Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -3,12k | 40,62k | Vente | 13,04 | 256,73k | -1,20% |
| 2026-04-27 | Ms. Julie RubinsteinPresident & COO | -4,33k | 61,62k | Automatic Disposition | 14,23 | 377,80k | -1,13% |
| 2026-04-27 | Ms. Julie RubinsteinPresident & COO | -14,71k | 84,86k | Derivative Exercise and Sale | 8,46 - 14,23 | 377,80k | - |
| 2026-04-22 | Ms. Julie RubinsteinPresident & COO | -44,17k | 243,06k | Derivative Exercise and Sale | 8,46 - 14,13 | 382,13k | - |
| 2026-04-22 | Ms. Julie RubinsteinPresident & COO | -13,01k | 181,72k | Automatic Disposition | 13,74 - 14,13 | 382,13k | -3,29% |
| 2026-04-17 | Ms. Julie RubinsteinPresident & COO | -56,05k | 300,82k | Derivative Exercise and Sale | 8,46 - 14,66 | 395,15k | - |
| 2026-04-17 | Ms. Julie RubinsteinPresident & COO | -13,01k | 189,92k | Automatic Disposition | 14,55 - 14,66 | 395,15k | -3,19% |
| 2026-04-14 | Ms. Julie RubinsteinPresident & COO | -44,17k | 264,55k | Derivative Exercise and Sale | 8,46 - 14,61 | 408,16k | - |
| 2026-04-14 | Ms. Julie RubinsteinPresident & COO | -13,01k | 188,05k | Automatic Disposition | 14,18 - 14,61 | 408,16k | -3,09% |
| 2026-04-09 | Ms. Julie RubinsteinPresident & COO | -44,17k | 252,42k | Derivative Exercise and Sale | 7,27 - 13,79 | 421,17k | - |
| 2026-04-09 | Ms. Julie RubinsteinPresident & COO | -13,01k | 176,74k | Automatic Disposition | 12,75 - 14,44 | 421,17k | -3,00% |
| 2026-04-08 | Mr. Francis T. LoCPO | -2,34k | 25,97k | Derivative Exercise and Sale | 3,99 - 15,07 | 273,65k | - |
| 2026-04-08 | Mr. Francis T. LoCPO | -20,22k | 304,72k | Automatic Disposition | 15,07 | 273,65k | -6,88% |
| 2026-04-08 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -10,00k | 148,50k | Automatic Disposition | 14,85 | 1,51M | -0,66% |
| 2026-04-06 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -120,60k | 1,77M | Automatic Disposition | 14,41 - 15,19 | 1,52M | -7,35% |
| 2026-04-06 | Ms. Julie RubinsteinPresident & COO | -56,05k | 339,80k | Derivative Exercise and Sale | 7,27 - 14,83 | 434,19k | - |
| 2026-04-06 | Ms. Julie RubinsteinPresident & COO | -13,01k | 185,38k | Automatic Disposition | 13,56 - 15,48 | 434,19k | -2,91% |
| 2026-04-01 | Ms. Julie RubinsteinPresident & COO | -29,44k | 213,62k | Derivative Exercise and Sale | 7,27 - 14,60 | 447,20k | - |
| 2026-04-01 | Ms. Julie RubinsteinPresident & COO | -8,68k | 126,02k | Automatic Disposition | 14,45 - 14,60 | 447,20k | -1,90% |
| 2026-03-27 | Ms. Julie RubinsteinPresident & COO | -44,17k | 258,60k | Derivative Exercise and Sale | 7,27 - 13,48 | 455,88k | - |
| 2026-03-27 | Ms. Julie RubinsteinPresident & COO | -13,01k | 171,61k | Automatic Disposition | 12,63 - 13,48 | 455,88k | -2,78% |
| 2026-03-24 | Ms. Julie RubinsteinPresident & COO | -13,01k | 182,59k | Automatic Disposition | 13,70 - 14,27 | 468,89k | -2,70% |
| 2026-03-24 | Ms. Julie RubinsteinPresident & COO | -44,17k | 298,56k | Derivative Exercise and Sale | 7,27 - 14,27 | 468,89k | - |
| 2026-03-19 | Ms. Julie RubinsteinPresident & COO | -13,01k | 175,17k | Automatic Disposition | 13,18 - 13,83 | 481,91k | -2,63% |
| 2026-03-19 | Ms. Julie RubinsteinPresident & COO | -44,17k | 286,82k | Derivative Exercise and Sale | 6,55 - 13,83 | 481,91k | - |
| 2026-03-16 | Ms. Julie RubinsteinPresident & COO | -44,17k | 299,45k | Derivative Exercise and Sale | 6,55 - 13,41 | 494,92k | - |
| 2026-03-16 | Ms. Julie RubinsteinPresident & COO | -13,01k | 173,48k | Automatic Disposition | 13,18 - 13,41 | 494,92k | -2,56% |
| 2026-03-11 | Ms. Julie RubinsteinPresident & COO | -44,17k | 295,58k | Derivative Exercise and Sale | 6,55 - 14,08 | 507,93k | - |
| 2026-03-11 | Ms. Julie RubinsteinPresident & COO | -122,52k | 1,61M | Vente | 13,17 | 507,93k | -19,43% |
| 2026-03-11 | Ms. Julie RubinsteinPresident & COO | -13,01k | 175,56k | Automatic Disposition | 12,96 - 14,08 | 507,93k | -2,50% |
| 2026-03-11 | Ms. Michelle GriffinIndependent Director | -15,39k | 214,13k | Vente | 13,91 | 15,63k | -49,63% |
| 2026-03-11 | Mr. Francis T. LoCPO | -30,59k | 430,75k | Automatic Disposition | 14,08 | 293,87k | -9,43% |
| 2026-03-11 | Ms. Susan BobulskyChief Commercial Officer of MRD | -41,34k | 544,42k | Vente | 13,17 | 427,78k | -8,81% |
| 2026-03-11 | Dr. Sharon BenzenoChief Commercial Officer of Immune Medicine | -63,10k | 831,07k | Vente | 13,17 | 272,75k | -18,79% |
| 2026-03-11 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -18,67k | 245,91k | Vente | 13,17 | 259,84k | -6,70% |
| 2026-03-11 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -470,27k | 6,19M | Vente | 13,17 | 1,52M | -23,60% |
| 2026-03-11 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -470,17k | 6,19M | Vente | 13,17 | 1,64M | -22,27% |
| 2026-03-06 | Ms. Julie RubinsteinPresident & COO | -68,33k | 435,60k | Derivative Exercise and Sale | 6,55 - 15,14 | 643,47k | - |
| 2026-03-06 | Ms. Julie RubinsteinPresident & COO | -13,01k | 193,52k | Automatic Disposition | 14,68 - 15,14 | 643,47k | -1,98% |
| 2026-03-05 | Mr. Francis T. LoCPO | -38,07k | 574,54k | Vente | 15,09 | 324,47k | -10,50% |
| 2026-03-03 | Ms. Michelle GriffinIndependent Director | -48,04k | 543,38k | Derivative Exercise and Sale | 3,99 - 15,30 | 15,39k | - |
| 2026-03-03 | Ms. Julie RubinsteinPresident & COO | -79,81k | 559,18k | Derivative Exercise and Sale | 6,55 - 16,60 | 575,24k | - |
| 2026-03-03 | Ms. Julie RubinsteinPresident & COO | -13,01k | 212,26k | Automatic Disposition | 16,00 - 16,60 | 575,24k | -2,21% |
| 2026-03-02 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -24,23k | 392,33k | Automatic Disposition | 15,72 - 16,52 | 1,16M | -2,05% |
| 2026-02-27 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -525,00k | 8,32M | Automatic Disposition | 15,49 - 16,15 | 1,07M | -32,83% |
| 2026-02-04 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -2,15k | 13,56k | Derivative Exercise and Sale | 12,14 - 18,46 | 3,22k | - |
| 2026-02-02 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -42,79k | 799,10k | Automatic Disposition | 18,60 - 19,00 | 1,18M | -3,50% |
| 2026-02-02 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -125,00k | 2,30M | Automatic Disposition | 18,44 | 1,60M | -7,25% |
| 2026-01-12 | Mr. Francis T. LoCPO | -79,59k | 797,11k | Derivative Exercise and Sale | 3,99 - 17,73 | 318,48k | - |
| 2026-01-12 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -4,29k | 25,14k | Derivative Exercise and Sale | 12,14 - 18,00 | 3,22k | - |
| 2026-01-06 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -10,00k | 164,40k | Automatic Disposition | 16,44 | 1,22M | -0,81% |
| 2025-12-22 | Mr. Francis T. LoCPO | -4,39k | 50,25k | Derivative Exercise and Sale | 3,99 - 17,50 | 318,48k | - |
| 2026-01-05 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -125,00k | 1,95M | Automatic Disposition | 15,59 | 1,72M | -6,76% |
| 2026-01-02 | Mr. Francis T. LoCPO | -3,13k | 37,78k | Derivative Exercise and Sale | 3,99 - 16,08 | 318,48k | - |
| 2025-12-15 | Mr. Francis T. LoCPO | -97,02k | 892,87k | Derivative Exercise and Sale | 3,99 - 15,57 | 318,48k | - |
| 2025-12-15 | Mr. Francis T. LoCPO | -16,87k | 262,63k | Automatic Disposition | 15,57 | 318,48k | -5,03% |
| 2025-12-10 | Dr. Robert M. HershbergIndependent Director | -22,97k | 367,49k | Vente | 16,00 | 46,72k | -32,96% |
| 2025-12-04 | Dr. Sharon BenzenoChief Commercial Officer of Immune Medicine | -12,60k | 108,54k | Derivative Exercise and Sale | 3,99 - 16,85 | 296,79k | - |
| 2025-12-03 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -37,21k | 672,52k | Automatic Disposition | 16,61 - 18,61 | 1,23M | -2,93% |
| 2025-11-28 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -110,11k | 893,68k | Derivative Exercise and Sale | 6,55 - 19,50 | 3,22k | - |
| 2025-11-28 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -52,71k | 1,03M | Automatic Disposition | 19,50 | 3,22k | -94,24% |
| 2025-11-26 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -160,73k | 3,07M | Automatic Disposition | 18,94 - 19,68 | 1,85M | -8,00% |
| 2025-11-20 | Dr. Sharon BenzenoChief Commercial Officer of Immune Medicine | -510,47k | 4,09M | Derivative Exercise and Sale | 3,99 - 16,91 | 296,79k | - |
| 2025-11-20 | Dr. Sharon BenzenoChief Commercial Officer of Immune Medicine | -95,93k | 1,59M | Automatic Disposition | 16,54 | 296,79k | -24,43% |
| 2025-11-17 | Mr. Kyle PiskelVP, CFO & Principal Accounting Officer | -238,00 | 3,34k | Vente | 14,05 | 55,93k | -0,42% |
| 2025-11-10 | Dr. Harlan S. RobinsCo-Founder & Chief Scientific Officer | -10,00k | 148,20k | Automatic Disposition | 14,82 | 1,27M | -0,78% |
| 2025-11-10 | Mr. Chad M. RobinsCo-Founder, CEO & Chairman | -89,27k | 1,32M | Automatic Disposition | 14,57 - 15,00 | 2,01M | -4,25% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
